Company has strengthened its financial position with a EUR 2.6 million equity financing, bringing its total available funding from grants and newly raised capital to more than EUR 9 million.
The proceeds will support the commercialization and strategic partnering of Genomtec’s proprietary diagnostic platforms, Genomtec ID® and OncoSNAAT®, while also accelerating the development of artificial intelligence tools designed to streamline molecular test development.
“We are pleased to have secured additional capital that enables us to execute the next phase of our commercialization strategy,” said Miron Tokarski, CEO and co-founder of Genomtec. “With funding secured, we can continue advancing strategic discussions around Genomtec ID and OncoSNAAT while investing in technologies that strengthen our competitive position, including AI-based solutions for molecular diagnostics development.”
In parallel, Genomtec is executing a nearly EUR 1.65 million AI-focused project funded by the Lower Silesian Intermediate Body. The initiative applies artificial intelligence and machine learning to automate the design of LAMP-based primers, significantly reducing the time and cost required to develop new molecular diagnostic tests.
The company will also continue advancing:
The company will also continue advancing:
• Commercialization and strategic partnering activities for Genomtec ID® and OncoSNAAT®;
• Further optimization of the Genomtec ID® platform;
• Development of OncoSNAAT®, a liquid biopsy-based oncology diagnostics technology.
Genomtec’s flagship Genomtec ID® platform enables rapid molecular diagnostics at the point of care through a portable system combining proprietary SNAAT® technology with integrated testing capabilities. The company’s OncoSNAAT® technology is being developed to support precision oncology through the detection of clinically relevant cancer-related genetic alterations.
